PD-1/PD-L1 antibodies are more precise and safer than traditional therapies in the treatment of prostate cancer and have some efficacy.
In recent years, immunosuppressive drugs such as PD-1/PD-L1 monoclonal antibodies have made a splash in clinical treatment, opening up new therapeutic hope for tumor patients. Because the drug has not yet been introduced in China, PD-1/PD-L1 monoclonal antibody remains a mystery to most oncology patients.
The PD-1/PD-L1 monoclonal antibody immunotherapy works by blocking the PD-1/PD-L1 signaling pathway in tumor cells, allowing the immune system to kill cancer cells directly.
PD-1/PD-L1 antibodies have shown initial, encouraging efficacy in a variety of other solid tumors, including prostate cancer.
Immunotherapy is more precisely targeted and safer than traditional treatments such as chemotherapy and radiotherapy, with prolonged survival and relatively less toxic side effects. In addition, PD-1/PD-L1 monoclonal antibody immunotherapy can be administered concurrently with other treatments.
It is important to note that PD-1/PD-L1 antibody drugs are prescription drugs and need to be used under the guidance of a physician with experience in the use of pharmaceuticals because they have certain toxic side effects; at the same time, overseas prescription drugs are strictly controlled and cannot be purchased in pharmacies or private purchasing channels.